U.S. markets closed

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
508.85+5.20 (+1.03%)
At close: 3:29PM IST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close503.65
Open509.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range493.60 - 515.00
52 Week Range312.00 - 564.75
Volume9,861,824
Avg. Volume9,939,478
Market Cap1.221T
Beta (5Y Monthly)0.40
PE Ratio (TTM)169.11
EPS (TTM)3.01
Earnings DateN/A
Forward Dividend & Yield6.75 (1.34%)
Ex-Dividend DateAug 19, 2020
1y Target Est567.59
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Barrons.com

      Why the Boom in India’s Pharmaceutical Stocks May Fade

      The Indian pharma stock surge dates to April, when the ban on exporting hydroxycholoroquine was lifted. The sector's stocks jumped, but the gains won't last as U.S. scrutiny returns.

    • Sun Pharma latest to sell COVID-19 drug favipiravir in India
      Reuters

      Sun Pharma latest to sell COVID-19 drug favipiravir in India

      India's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world's third worst-hit nation. Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge of 50,000-plus infections for the sixth straight day on Tuesday. Sun's version of favipiravir, to be called FluGuard, will cost 35 rupees (47 cents) per 200 mg tablet, making it the cheapest version available.

    • Sun Pharma testing plant-based drug as potential COVID-19 treatment
      Reuters

      Sun Pharma testing plant-based drug as potential COVID-19 treatment

      Indian drugmaker Sun Pharmaceutical Industries Ltd said on Friday it was testing a plant-derived drug, AQCH, for the potential treatment of COVID-19 as part of a mid-stage trial, with results expected by October. AQCH is derived from tropical, climbing shrub cocculus hirsutus, which is used in Asia for its apparent medicinal properties. The company said the trial will be conducted across 12 centers in India in 210 patients and a human safety study of the drug has been completed.